Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia

Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypot...

Full description

Saved in:
Bibliographic Details
Published inPsychiatry research Vol. 186; no. 1; pp. 23 - 27
Main Authors Sumiyoshi, Tomiki, Higuchi, Yuko, Matsui, Mie, Itoh, Hiroko, Uehara, Takashi, Itoh, Toru, Arai, Hirofumi, Takamiya, Chieko, Suzuki, Michio, Kurachi, Masayoshi
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ireland Ltd 30.03.2011
Elsevier
Subjects
Online AccessGet full text
ISSN0165-1781
1872-7123
DOI10.1016/j.psychres.2010.07.049

Cover

Abstract Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3 months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.
AbstractList Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.
Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.
Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3 months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.
Abstract Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has been suggested to be related to the psychotic symptoms and cognitive impairment of schizophrenia. This study was conducted to test the hypothesis that the ability of atypical antipsychotic drugs to ameliorate positive symptoms and cognitive function relevant to daily living would be predicted by baseline EPUFAs concentrations in the erythrocyte membrane in subjects with schizophrenia. A total of 24 actively psychotic patients with schizophrenia participated in the study. After blood drawing, they were treated with olanzapine or perospirone. The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for Assessment of Negative symptoms (SANS), as well as the script tasks, a measure of event schema recognition, were administered at baseline and 3 months after the start of treatment. Erythrocyte membrane fatty acid levels were analysed using a gas chromatography system. Scores of SAPS and SANS, as well as script task performance, were improved during treatment with either antipsychotic drug. Regression analysis indicates baseline EPUFAs concentrations were positively and negatively related with percent improvement of positive symptoms and script task performance, respectively. The results of this study suggest composition of phospholipids in the erythrocyte membrane provide a feasible marker to predict treatment response in patients with schizophrenia.
Author Sumiyoshi, Tomiki
Higuchi, Yuko
Suzuki, Michio
Kurachi, Masayoshi
Matsui, Mie
Itoh, Toru
Takamiya, Chieko
Itoh, Hiroko
Uehara, Takashi
Arai, Hirofumi
Author_xml – sequence: 1
  givenname: Tomiki
  surname: Sumiyoshi
  fullname: Sumiyoshi, Tomiki
  email: tomikisumiyoshi840@hotmail.com
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 2
  givenname: Yuko
  surname: Higuchi
  fullname: Higuchi, Yuko
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 3
  givenname: Mie
  surname: Matsui
  fullname: Matsui, Mie
  organization: Core Research for Evolutional Science and Technology, Japan Science and Technology Corporation, Tokyo, Japan
– sequence: 4
  givenname: Hiroko
  surname: Itoh
  fullname: Itoh, Hiroko
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 5
  givenname: Takashi
  surname: Uehara
  fullname: Uehara, Takashi
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 6
  givenname: Toru
  surname: Itoh
  fullname: Itoh, Toru
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 7
  givenname: Hirofumi
  surname: Arai
  fullname: Arai, Hirofumi
  organization: Department of Psychology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 8
  givenname: Chieko
  surname: Takamiya
  fullname: Takamiya, Chieko
  organization: Department of Psychology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 9
  givenname: Michio
  surname: Suzuki
  fullname: Suzuki, Michio
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
– sequence: 10
  givenname: Masayoshi
  surname: Kurachi
  fullname: Kurachi, Masayoshi
  organization: Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23923484$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20800904$$D View this record in MEDLINE/PubMed
BookMark eNqNkk9r3DAQxUVJaTZpv0LQpfTkjSRbawlKaQn9E0jIoS30JibymGhrS66kDWw-fWV2l0AOTUEgEL_3ZjRvTsiRDx4JOeNsyRlfna-XU9rau4hpKVh5ZO2SNfoFWXDViqrloj4iiwLKireKH5OTlNaMMcG1fkWOBVOMadYsyK9rHG8jeKQ95LylYF1HB7zHIVEoh04RO2dziDT0NEeEPKLPtBSegk9InaeljeCdpcneuYcwlaa8g9fkZQ9Dwjf7-5T8_PL5x8W36urm6-XFp6vKyrbOlQTb6t5qjjUorRTUILFbdRqE7YSQwGUteg6oBALvrZJSigY6paFueFGdknc73ymGPxtM2YwuWRyG8qewSUbJpm61bkUhz_bk5nbEzkzRjRC35jCMArzdA5AsDH0Zi3Xpkau1qBs1c-93nI0hpYi9sS5DdsHnCG4wnJk5I7M2h4zMnJFhrSkZFfnqifxQ4Vnhx52whIP3DqNJ1qG3JaCINpsuuOctPjyxsIMr2cHwG7eY1mETfUnLcJOEYeb7vEHzAvGyO43iq38b_E8HfwGN59qr
CODEN PSRSDR
CitedBy_id crossref_primary_10_1016_j_glohj_2020_01_004
crossref_primary_10_1016_j_plefa_2023_102604
crossref_primary_10_1016_j_jchromb_2015_05_011
crossref_primary_10_1210_endocr_bqad025
crossref_primary_10_3389_fpsyt_2023_1188452
crossref_primary_10_1016_j_schres_2012_08_014
crossref_primary_10_3389_fncel_2023_1163764
crossref_primary_10_3390_ijms20215257
crossref_primary_10_1515_cpp_2016_0021
crossref_primary_10_1016_j_psychres_2012_02_019
crossref_primary_10_3390_ijms25094824
crossref_primary_10_1016_j_ejphar_2025_177469
crossref_primary_10_1016_j_pnpbp_2024_111011
crossref_primary_10_1111_acps_12388
crossref_primary_10_1016_j_bionps_2024_100089
crossref_primary_10_1177_2156587213488788
crossref_primary_10_1371_journal_pone_0068717
crossref_primary_10_1038_s41537_022_00214_2
crossref_primary_10_3389_fpsyt_2023_1089724
crossref_primary_10_1186_s12888_016_1006_3
crossref_primary_10_3389_fpsyt_2024_1361997
crossref_primary_10_1016_j_plefa_2017_03_006
crossref_primary_10_1016_j_plefa_2023_102578
Cites_doi 10.1016/S0165-1781(99)00051-7
10.1093/schbul/sbi058
10.1016/S0006-3223(02)01397-5
10.1016/0920-9964(94)90014-0
10.1016/S0006-3223(02)01443-9
10.1016/0920-9964(94)90084-1
10.1016/j.schres.2008.01.020
10.1016/S0920-9964(97)00151-5
10.1016/S0278-5846(01)00211-1
10.1016/S0140-6736(05)79168-6
10.1016/S0920-9964(01)00334-6
10.1016/j.plefa.2003.08.010
10.1016/j.schres.2006.11.027
10.1016/S0165-1781(99)00014-1
10.1016/0165-1781(89)90146-7
10.1016/S0006-3223(99)00092-X
10.1016/j.pnpbp.2006.11.013
10.1016/j.psychres.2006.05.025
10.1016/S0920-9964(98)00016-4
10.1016/S0006-3223(00)00986-0
10.1093/oxfordjournals.schbul.a033376
10.1016/0022-3956(95)00001-L
10.1016/S0165-1781(96)02993-9
10.1016/j.schres.2008.09.027
10.1016/S0022-3956(01)00048-6
10.1016/S0165-1781(03)00220-8
10.1093/jn/124.12.2466
10.1093/oxfordjournals.schbul.a007140
10.1016/0165-0327(95)00092-5
10.1016/j.schres.2008.03.009
10.1016/S0022-2275(20)43209-2
10.1016/0920-9964(94)90045-0
10.1016/j.plefa.2008.11.004
10.1016/j.schres.2008.11.025
10.1038/sj.mp.4002000
10.1054/plef.2000.0191
10.1016/j.pscychresns.2008.07.005
10.1007/s00213-004-1924-5
10.1016/0920-9964(94)90046-9
10.1016/j.psychres.2005.09.006
10.1016/j.pnpbp.2003.09.010
10.1016/S0920-9964(02)00284-0
ContentType Journal Article
Copyright 2010 Elsevier Ireland Ltd
Elsevier Ireland Ltd
2015 INIST-CNRS
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
Copyright_xml – notice: 2010 Elsevier Ireland Ltd
– notice: Elsevier Ireland Ltd
– notice: 2015 INIST-CNRS
– notice: Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.psychres.2010.07.049
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE



Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1872-7123
EndPage 27
ExternalDocumentID 20800904
23923484
10_1016_j_psychres_2010_07_049
S0165178110004816
1_s2_0_S0165178110004816
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29P
4.4
457
4G.
53G
5VS
7-5
71M
8P~
9JM
9JO
AABNK
AADFP
AAEDT
AAEDW
AAGJA
AAGKA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABWVN
ABXDB
ACDAQ
ACGFS
ACHQT
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ACXNI
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEG
HMK
HMO
HMQ
HMW
HVGLF
HZ~
IHE
J1W
KOM
M29
M2V
M39
M3V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPS
SSB
SSH
SSN
SSY
SSZ
T5K
UV1
WUQ
Z5R
ZGI
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AADPK
AAIAV
ABLVK
ABYKQ
AFYLN
AJBFU
EFLBG
LCYCR
ZA5
AAYXX
ACLOT
CITATION
~HD
AGRNS
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c573t-5ac79fc91e3a8988a3a5ed6d9a2cd225a1532f1ae82ea1fc855524ad89a3411e3
IEDL.DBID .~1
ISSN 0165-1781
IngestDate Tue Sep 30 22:48:45 EDT 2025
Mon Jul 21 05:58:51 EDT 2025
Mon Jul 21 09:17:14 EDT 2025
Wed Oct 01 04:10:09 EDT 2025
Thu Apr 24 23:06:31 EDT 2025
Fri Feb 23 02:33:51 EST 2024
Sun Feb 23 10:19:16 EST 2025
Tue Aug 26 16:35:31 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Schizophrenia
Essential polyunsaturated fatty acids
Phospholipids
Cognition
Antipsychotic drugs
Social function
Neuroleptic
Psychotropic
Polyunsaturated fatty acid
Pharmacotherapy
Phospholipid
Lipids
Fatty acids
Psychosis
Chronic
Treatment
Antipsychotic
Essential fatty acid
Predictive factor
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c573t-5ac79fc91e3a8988a3a5ed6d9a2cd225a1532f1ae82ea1fc855524ad89a3411e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20800904
PQID 854379972
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_854379972
pubmed_primary_20800904
pascalfrancis_primary_23923484
crossref_citationtrail_10_1016_j_psychres_2010_07_049
crossref_primary_10_1016_j_psychres_2010_07_049
elsevier_sciencedirect_doi_10_1016_j_psychres_2010_07_049
elsevier_clinicalkeyesjournals_1_s2_0_S0165178110004816
elsevier_clinicalkey_doi_10_1016_j_psychres_2010_07_049
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-03-30
PublicationDateYYYYMMDD 2011-03-30
PublicationDate_xml – month: 03
  year: 2011
  text: 2011-03-30
  day: 30
PublicationDecade 2010
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
– name: Ireland
PublicationTitle Psychiatry research
PublicationTitleAlternate Psychiatry Res
PublicationYear 2011
Publisher Elsevier Ireland Ltd
Elsevier
Publisher_xml – name: Elsevier Ireland Ltd
– name: Elsevier
References Andreasen (bb0005) 1983
Khan, Evans, Gunna, Scheffer, Parikh, Mahadik (bb0100) 2002; 58
McNamara, Able, Jandacek, Rider, Tso (bb0120) 2009; 107
Evans, Parikh, Khan, Coussons, Buckley, Mahadik (bb0060) 2003; 69
Fenton, Hibbeln, Knable (bb0065) 2000; 47
Maes, Smith, Christophe, Cosyns, Desnyder, Meltzer (bb0110) 1996; 38
Hibbeln (bb0080) 1998; 351
Doris, Wahle, MacDonald, Morris, Coffey, Muir, Blackwood (bb0050) 1998; 31
Meltzer, Li, Kaneda, Ichikawa (bb0130) 2003; 27
Ohara (bb0140) 2007; 31
McNamara, Jandacek, Rider, Tso, Hahn, Richtand, Stanford (bb0125) 2007; 91
Vaddadi, Courtney, Gilleard, Manku, Horrobin (bb0195) 1989; 27
Connor, Neuringer, Lin (bb0040) 1990; 31
Polymeropoulos, Licamele, Volpi, Mack, Mitkus, Carstea, Getoor, Thompson, Lavedan (bb0155) 2009; 108
Andreasen (bb0010) 1983
Peet, Horrobin (bb0145) 2002; 36
Maes, Christophe, Delanghe, Altamura, Neels, Meltzer (bb0105) 1999; 85
Sumiyoshi, Hasegawa, Jayathilake, Meltzer (bb0175) 1997; 69
Yao, van Kammen, Welker (bb0215) 1994; 13
Sumiyoshi, Roy, Kim, Jayathilake, Lee, Sumiyoshi, Meltzer (bb0190) 2004; 177
Elizabeth Sublette, Milak, Hibbeln, Freed, Oquendo, Malone, Parsey, John Mann (bb0055) 2009; 80
Delion, Chalon, Herault, Guilloteau, Besnard, Durand (bb0045) 1994; 124
Arvindakshan, Sitasawad, Debsikdar, Ghate, Evans, Horrobin, Bennet, Ranjekar, Mahadik (bb0020) 2003; 53
Yao, van Kammen, Gurklis (bb0210) 1994; 13
Bennett, Horrobin (bb0030) 2000; 63
Richardson, Allen, Hajnal, Cox, Easton, Puri (bb0170) 2001; 25
Yao, Stanley, Reddy, Keshavan, Pettegrew (bb0200) 2002; 52
Kaddurah-Daouk, McEvoy, Baillie, Lee, Yao, Doraiswamy, Krishnan (bb0095) 2007; 12
Arvindakshan, Ghate, Ranjekar, Evans, Mahadik (bb0015) 2003; 62
Meltzer, McGurk (bb0135) 1999; 25
Matsui, Sumiyoshi, Yuuki, Kato, Kurachi (bb0115) 2006; 143
Ranjekar, Hinge, Hegde, Ghate, Kale, Sitasawad, Wagh, Debsikdar (bb0160) 2003; 121
Hagan, Jones (bb0075) 2005; 31
Chan, Chiu, Lam, Pang, Chow (bb0035) 1999; 87
Condray, Yao, Steinhauer, van Kammen, Reddy, Morrow (bb0220) 2008; 106
Assies, Lieverse, Vreken, Wanders, Dingemans, Linszen (bb0025) 2001; 49
Peet, Laugharne, Rangarajan, Horrobin, Reynolds (bb0150) 1995; 29
Glen, Glen, Horrobin, Vaddadi, Spellman, Morse-Fisher, Ellis (bb0070) 1994; 12
Sumiyoshi, Higuchi, Itoh, Matsui, Arai, Suzuki, Kurachi, Kawasaki (bb0180) 2009; 172
Horrobin (bb0090) 1998; 30
Sumiyoshi, Matsui, Itoh, Higuchi, Arai, Takamiya, Kurachi (bb0185) 2008; 157
Higuchi, Sumiyoshi, Kawasaki, Matsui, Arai, Kurachi (bb0085) 2008; 101
Yao, van Kammen (bb0205) 1994; 11
Reddy, Keshavan, Yao (bb0165) 2004; 30
Horrobin (10.1016/j.psychres.2010.07.049_bb0090) 1998; 30
Yao (10.1016/j.psychres.2010.07.049_bb0205) 1994; 11
Polymeropoulos (10.1016/j.psychres.2010.07.049_bb0155) 2009; 108
Higuchi (10.1016/j.psychres.2010.07.049_bb0085) 2008; 101
Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0190) 2004; 177
Reddy (10.1016/j.psychres.2010.07.049_bb0165) 2004; 30
McNamara (10.1016/j.psychres.2010.07.049_bb0125) 2007; 91
Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0180) 2009; 172
Peet (10.1016/j.psychres.2010.07.049_bb0145) 2002; 36
McNamara (10.1016/j.psychres.2010.07.049_bb0120) 2009; 107
Assies (10.1016/j.psychres.2010.07.049_bb0025) 2001; 49
Chan (10.1016/j.psychres.2010.07.049_bb0035) 1999; 87
Doris (10.1016/j.psychres.2010.07.049_bb0050) 1998; 31
Andreasen (10.1016/j.psychres.2010.07.049_bb0005) 1983
Matsui (10.1016/j.psychres.2010.07.049_bb0115) 2006; 143
Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0185) 2008; 157
Yao (10.1016/j.psychres.2010.07.049_bb0215) 1994; 13
Kaddurah-Daouk (10.1016/j.psychres.2010.07.049_bb0095) 2007; 12
Bennett (10.1016/j.psychres.2010.07.049_bb0030) 2000; 63
Meltzer (10.1016/j.psychres.2010.07.049_bb0135) 1999; 25
Condray (10.1016/j.psychres.2010.07.049_bb0220) 2008; 106
Richardson (10.1016/j.psychres.2010.07.049_bb0170) 2001; 25
Andreasen (10.1016/j.psychres.2010.07.049_bb0010) 1983
Elizabeth Sublette (10.1016/j.psychres.2010.07.049_bb0055) 2009; 80
Connor (10.1016/j.psychres.2010.07.049_bb0040) 1990; 31
Yao (10.1016/j.psychres.2010.07.049_bb0210) 1994; 13
Maes (10.1016/j.psychres.2010.07.049_bb0105) 1999; 85
Khan (10.1016/j.psychres.2010.07.049_bb0100) 2002; 58
Delion (10.1016/j.psychres.2010.07.049_bb0045) 1994; 124
Evans (10.1016/j.psychres.2010.07.049_bb0060) 2003; 69
Peet (10.1016/j.psychres.2010.07.049_bb0150) 1995; 29
Yao (10.1016/j.psychres.2010.07.049_bb0200) 2002; 52
Arvindakshan (10.1016/j.psychres.2010.07.049_bb0015) 2003; 62
Sumiyoshi (10.1016/j.psychres.2010.07.049_bb0175) 1997; 69
Maes (10.1016/j.psychres.2010.07.049_bb0110) 1996; 38
Hibbeln (10.1016/j.psychres.2010.07.049_bb0080) 1998; 351
Glen (10.1016/j.psychres.2010.07.049_bb0070) 1994; 12
Ohara (10.1016/j.psychres.2010.07.049_bb0140) 2007; 31
Vaddadi (10.1016/j.psychres.2010.07.049_bb0195) 1989; 27
Arvindakshan (10.1016/j.psychres.2010.07.049_bb0020) 2003; 53
Hagan (10.1016/j.psychres.2010.07.049_bb0075) 2005; 31
Meltzer (10.1016/j.psychres.2010.07.049_bb0130) 2003; 27
Ranjekar (10.1016/j.psychres.2010.07.049_bb0160) 2003; 121
Fenton (10.1016/j.psychres.2010.07.049_bb0065) 2000; 47
References_xml – volume: 31
  start-page: 830
  year: 2005
  end-page: 853
  ident: bb0075
  article-title: Predicting drug efficacy for cognitive deficits in schizophrenia
  publication-title: Schizophrenia Bulletin
– volume: 157
  start-page: 87
  year: 2008
  end-page: 93
  ident: bb0185
  article-title: Essential polyunsaturated fatty acids and social cognition in schizophrenia
  publication-title: Psychiatry Research
– volume: 27
  start-page: 1159
  year: 2003
  end-page: 1172
  ident: bb0130
  article-title: Serotonin receptors: their key role in drugs to treat schizophrenia
  publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry
– volume: 121
  start-page: 109
  year: 2003
  end-page: 122
  ident: bb0160
  article-title: Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients
  publication-title: Psychiatry Research
– volume: 63
  start-page: 47
  year: 2000
  end-page: 59
  ident: bb0030
  article-title: Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update
  publication-title: Prostaglandins Leukotriene and Essential Fatty Acids
– volume: 172
  start-page: 180
  year: 2009
  end-page: 183
  ident: bb0180
  article-title: Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA
  publication-title: Psychiatry Research Neuroimaging
– volume: 31
  start-page: 237
  year: 1990
  end-page: 247
  ident: bb0040
  article-title: Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys
  publication-title: Jounral of Lipid Research
– volume: 36
  start-page: 7
  year: 2002
  end-page: 18
  ident: bb0145
  article-title: A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms
  publication-title: Journal of Psychiatry Research
– volume: 107
  start-page: 150
  year: 2009
  end-page: 157
  ident: bb0120
  article-title: Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis
  publication-title: Schizophrenia Research
– volume: 25
  start-page: 233
  year: 1999
  end-page: 255
  ident: bb0135
  article-title: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
  publication-title: Schizophrenia Bulletin
– volume: 31
  start-page: 469
  year: 2007
  end-page: 474
  ident: bb0140
  article-title: The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia
  publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry
– volume: 30
  start-page: 193
  year: 1998
  end-page: 208
  ident: bb0090
  article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
  publication-title: Schizophrenia Research
– volume: 25
  start-page: 1513
  year: 2001
  end-page: 1521
  ident: bb0170
  article-title: Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes
  publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry
– volume: 124
  start-page: 2466
  year: 1994
  end-page: 2476
  ident: bb0045
  article-title: Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats
  publication-title: Journal of Nutrition
– volume: 69
  start-page: 113
  year: 1997
  end-page: 121
  ident: bb0175
  article-title: Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine
  publication-title: Psychiatry Research
– volume: 47
  start-page: 8
  year: 2000
  end-page: 21
  ident: bb0065
  article-title: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia
  publication-title: Biological Psychiatry
– volume: 27
  start-page: 313
  year: 1989
  end-page: 323
  ident: bb0195
  article-title: A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia
  publication-title: Psychiatry Research
– volume: 58
  start-page: 1
  year: 2002
  end-page: 10
  ident: bb0100
  article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics
  publication-title: Schizophrenia Research
– volume: 143
  start-page: 179
  year: 2006
  end-page: 187
  ident: bb0115
  article-title: Impairment of event schema in patients with schizophrenia: examination of script for shopping at supermarket
  publication-title: Psychiatry Research
– volume: 29
  start-page: 227
  year: 1995
  end-page: 232
  ident: bb0150
  article-title: Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients
  publication-title: Jounral of Psychiatry Research
– volume: 62
  start-page: 195
  year: 2003
  end-page: 204
  ident: bb0015
  article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia
  publication-title: Schizophrenia Research
– volume: 91
  start-page: 37
  year: 2007
  end-page: 50
  ident: bb0125
  article-title: Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications
  publication-title: Schizophrenia Research
– volume: 101
  start-page: 320
  year: 2008
  end-page: 330
  ident: bb0085
  article-title: Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300
  publication-title: Schizophrenia Research
– volume: 13
  start-page: 217
  year: 1994
  end-page: 226
  ident: bb0215
  article-title: Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition
  publication-title: Schizophrenia Research
– volume: 53
  start-page: 56
  year: 2003
  end-page: 64
  ident: bb0020
  article-title: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients
  publication-title: Biological Psychiatry
– year: 1983
  ident: bb0005
  article-title: Scale for the Assessment of Negative Symptoms (SANS)
– volume: 69
  start-page: 393
  year: 2003
  end-page: 399
  ident: bb0060
  article-title: Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment
  publication-title: Prostaglandins Leukotrienes and Essent Fatty Acids
– volume: 85
  start-page: 275
  year: 1999
  end-page: 291
  ident: bb0105
  article-title: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients
  publication-title: Psychiatry Research
– volume: 106
  start-page: 13
  year: 2008
  end-page: 28
  ident: bb0220
  article-title: Semantic memory in schizophrenia: association with cell membrane essential fatty acids
  publication-title: Schizophrenia Research
– volume: 87
  start-page: 169
  year: 1999
  end-page: 181
  ident: bb0035
  article-title: A breakdown of event schemas in patients with schizophrenia: an examination of their script for dining at restaurants
  publication-title: Psychiatry Research
– year: 1983
  ident: bb0010
  article-title: Scale for the Assessment of Positive Symptoms (SAPS)
– volume: 12
  start-page: 934
  year: 2007
  end-page: 945
  ident: bb0095
  article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia
  publication-title: Molecular Psychiatry
– volume: 12
  start-page: 53
  year: 1994
  end-page: 61
  ident: bb0070
  article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases
  publication-title: Schizophrenia Research
– volume: 13
  start-page: 227
  year: 1994
  end-page: 232
  ident: bb0210
  article-title: Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures
  publication-title: Schizophrenia Research
– volume: 11
  start-page: 209
  year: 1994
  end-page: 216
  ident: bb0205
  article-title: Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity
  publication-title: Schizophrenia Research
– volume: 351
  start-page: 1213
  year: 1998
  ident: bb0080
  article-title: Fish consumption and major depression
  publication-title: Lancet
– volume: 52
  start-page: 823
  year: 2002
  end-page: 830
  ident: bb0200
  article-title: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites
  publication-title: Biological Psychiatry
– volume: 31
  start-page: 185
  year: 1998
  end-page: 196
  ident: bb0050
  article-title: Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia
  publication-title: Schizophrenia Research
– volume: 30
  start-page: 901
  year: 2004
  end-page: 911
  ident: bb0165
  article-title: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline
  publication-title: Schizophrenia Bulletin
– volume: 177
  start-page: 79
  year: 2004
  end-page: 83
  ident: bb0190
  article-title: Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia
  publication-title: Psychopharmacology (Berl)
– volume: 80
  start-page: 57
  year: 2009
  end-page: 64
  ident: bb0055
  article-title: Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression
  publication-title: Prostaglandins Leukotriene Essential Fatty Acids
– volume: 38
  start-page: 35
  year: 1996
  end-page: 46
  ident: bb0110
  article-title: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids
  publication-title: Journal of Affective Disorders
– volume: 49
  start-page: 510
  year: 2001
  end-page: 522
  ident: bb0025
  article-title: Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group
  publication-title: Biological Psychiatry
– volume: 108
  start-page: 134
  year: 2009
  end-page: 142
  ident: bb0155
  article-title: Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia
  publication-title: Schizophrenia Research
– volume: 87
  start-page: 169
  year: 1999
  ident: 10.1016/j.psychres.2010.07.049_bb0035
  article-title: A breakdown of event schemas in patients with schizophrenia: an examination of their script for dining at restaurants
  publication-title: Psychiatry Research
  doi: 10.1016/S0165-1781(99)00051-7
– volume: 31
  start-page: 830
  year: 2005
  ident: 10.1016/j.psychres.2010.07.049_bb0075
  article-title: Predicting drug efficacy for cognitive deficits in schizophrenia
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/schbul/sbi058
– volume: 52
  start-page: 823
  year: 2002
  ident: 10.1016/j.psychres.2010.07.049_bb0200
  article-title: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(02)01397-5
– volume: 11
  start-page: 209
  year: 1994
  ident: 10.1016/j.psychres.2010.07.049_bb0205
  article-title: Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(94)90014-0
– year: 1983
  ident: 10.1016/j.psychres.2010.07.049_bb0010
– volume: 53
  start-page: 56
  year: 2003
  ident: 10.1016/j.psychres.2010.07.049_bb0020
  article-title: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(02)01443-9
– volume: 12
  start-page: 53
  year: 1994
  ident: 10.1016/j.psychres.2010.07.049_bb0070
  article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(94)90084-1
– volume: 101
  start-page: 320
  year: 2008
  ident: 10.1016/j.psychres.2010.07.049_bb0085
  article-title: Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300
  publication-title: Schizophrenia Research
  doi: 10.1016/j.schres.2008.01.020
– volume: 30
  start-page: 193
  year: 1998
  ident: 10.1016/j.psychres.2010.07.049_bb0090
  article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(97)00151-5
– volume: 25
  start-page: 1513
  year: 2001
  ident: 10.1016/j.psychres.2010.07.049_bb0170
  article-title: Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes
  publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry
  doi: 10.1016/S0278-5846(01)00211-1
– volume: 351
  start-page: 1213
  year: 1998
  ident: 10.1016/j.psychres.2010.07.049_bb0080
  article-title: Fish consumption and major depression
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)79168-6
– volume: 58
  start-page: 1
  year: 2002
  ident: 10.1016/j.psychres.2010.07.049_bb0100
  article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(01)00334-6
– volume: 69
  start-page: 393
  year: 2003
  ident: 10.1016/j.psychres.2010.07.049_bb0060
  article-title: Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment
  publication-title: Prostaglandins Leukotrienes and Essent Fatty Acids
  doi: 10.1016/j.plefa.2003.08.010
– volume: 91
  start-page: 37
  year: 2007
  ident: 10.1016/j.psychres.2010.07.049_bb0125
  article-title: Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications
  publication-title: Schizophrenia Research
  doi: 10.1016/j.schres.2006.11.027
– volume: 85
  start-page: 275
  year: 1999
  ident: 10.1016/j.psychres.2010.07.049_bb0105
  article-title: Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients
  publication-title: Psychiatry Research
  doi: 10.1016/S0165-1781(99)00014-1
– volume: 27
  start-page: 313
  year: 1989
  ident: 10.1016/j.psychres.2010.07.049_bb0195
  article-title: A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia
  publication-title: Psychiatry Research
  doi: 10.1016/0165-1781(89)90146-7
– volume: 47
  start-page: 8
  year: 2000
  ident: 10.1016/j.psychres.2010.07.049_bb0065
  article-title: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(99)00092-X
– volume: 31
  start-page: 469
  year: 2007
  ident: 10.1016/j.psychres.2010.07.049_bb0140
  article-title: The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia
  publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry
  doi: 10.1016/j.pnpbp.2006.11.013
– volume: 157
  start-page: 87
  year: 2008
  ident: 10.1016/j.psychres.2010.07.049_bb0185
  article-title: Essential polyunsaturated fatty acids and social cognition in schizophrenia
  publication-title: Psychiatry Research
  doi: 10.1016/j.psychres.2006.05.025
– volume: 31
  start-page: 185
  year: 1998
  ident: 10.1016/j.psychres.2010.07.049_bb0050
  article-title: Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(98)00016-4
– volume: 49
  start-page: 510
  year: 2001
  ident: 10.1016/j.psychres.2010.07.049_bb0025
  article-title: Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group
  publication-title: Biological Psychiatry
  doi: 10.1016/S0006-3223(00)00986-0
– volume: 25
  start-page: 233
  year: 1999
  ident: 10.1016/j.psychres.2010.07.049_bb0135
  article-title: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/oxfordjournals.schbul.a033376
– volume: 29
  start-page: 227
  year: 1995
  ident: 10.1016/j.psychres.2010.07.049_bb0150
  article-title: Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients
  publication-title: Jounral of Psychiatry Research
  doi: 10.1016/0022-3956(95)00001-L
– volume: 69
  start-page: 113
  year: 1997
  ident: 10.1016/j.psychres.2010.07.049_bb0175
  article-title: Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine
  publication-title: Psychiatry Research
  doi: 10.1016/S0165-1781(96)02993-9
– volume: 107
  start-page: 150
  year: 2009
  ident: 10.1016/j.psychres.2010.07.049_bb0120
  article-title: Chronic risperidone treatment preferentially increases rat erythrocyte and prefrontal cortex omega-3 fatty acid composition: evidence for augmented biosynthesis
  publication-title: Schizophrenia Research
  doi: 10.1016/j.schres.2008.09.027
– volume: 36
  start-page: 7
  year: 2002
  ident: 10.1016/j.psychres.2010.07.049_bb0145
  article-title: A dose-ranging exploratory study of the effects of ethyl- eicosapentaenoate in patients with persistent schizophrenic symptoms
  publication-title: Journal of Psychiatry Research
  doi: 10.1016/S0022-3956(01)00048-6
– volume: 121
  start-page: 109
  year: 2003
  ident: 10.1016/j.psychres.2010.07.049_bb0160
  article-title: Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients
  publication-title: Psychiatry Research
  doi: 10.1016/S0165-1781(03)00220-8
– volume: 124
  start-page: 2466
  year: 1994
  ident: 10.1016/j.psychres.2010.07.049_bb0045
  article-title: Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotonergic neurotransmission in rats
  publication-title: Journal of Nutrition
  doi: 10.1093/jn/124.12.2466
– volume: 30
  start-page: 901
  year: 2004
  ident: 10.1016/j.psychres.2010.07.049_bb0165
  article-title: Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline
  publication-title: Schizophrenia Bulletin
  doi: 10.1093/oxfordjournals.schbul.a007140
– volume: 38
  start-page: 35
  year: 1996
  ident: 10.1016/j.psychres.2010.07.049_bb0110
  article-title: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids
  publication-title: Journal of Affective Disorders
  doi: 10.1016/0165-0327(95)00092-5
– year: 1983
  ident: 10.1016/j.psychres.2010.07.049_bb0005
– volume: 106
  start-page: 13
  year: 2008
  ident: 10.1016/j.psychres.2010.07.049_bb0220
  article-title: Semantic memory in schizophrenia: association with cell membrane essential fatty acids
  publication-title: Schizophrenia Research
  doi: 10.1016/j.schres.2008.03.009
– volume: 31
  start-page: 237
  year: 1990
  ident: 10.1016/j.psychres.2010.07.049_bb0040
  article-title: Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys
  publication-title: Jounral of Lipid Research
  doi: 10.1016/S0022-2275(20)43209-2
– volume: 13
  start-page: 217
  year: 1994
  ident: 10.1016/j.psychres.2010.07.049_bb0215
  article-title: Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(94)90045-0
– volume: 80
  start-page: 57
  year: 2009
  ident: 10.1016/j.psychres.2010.07.049_bb0055
  article-title: Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression
  publication-title: Prostaglandins Leukotriene Essential Fatty Acids
  doi: 10.1016/j.plefa.2008.11.004
– volume: 108
  start-page: 134
  year: 2009
  ident: 10.1016/j.psychres.2010.07.049_bb0155
  article-title: Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/j.schres.2008.11.025
– volume: 12
  start-page: 934
  year: 2007
  ident: 10.1016/j.psychres.2010.07.049_bb0095
  article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia
  publication-title: Molecular Psychiatry
  doi: 10.1038/sj.mp.4002000
– volume: 63
  start-page: 47
  year: 2000
  ident: 10.1016/j.psychres.2010.07.049_bb0030
  article-title: Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update
  publication-title: Prostaglandins Leukotriene and Essential Fatty Acids
  doi: 10.1054/plef.2000.0191
– volume: 172
  start-page: 180
  year: 2009
  ident: 10.1016/j.psychres.2010.07.049_bb0180
  article-title: Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA
  publication-title: Psychiatry Research Neuroimaging
  doi: 10.1016/j.pscychresns.2008.07.005
– volume: 177
  start-page: 79
  year: 2004
  ident: 10.1016/j.psychres.2010.07.049_bb0190
  article-title: Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s00213-004-1924-5
– volume: 13
  start-page: 227
  year: 1994
  ident: 10.1016/j.psychres.2010.07.049_bb0210
  article-title: Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures
  publication-title: Schizophrenia Research
  doi: 10.1016/0920-9964(94)90046-9
– volume: 143
  start-page: 179
  year: 2006
  ident: 10.1016/j.psychres.2010.07.049_bb0115
  article-title: Impairment of event schema in patients with schizophrenia: examination of script for shopping at supermarket
  publication-title: Psychiatry Research
  doi: 10.1016/j.psychres.2005.09.006
– volume: 27
  start-page: 1159
  year: 2003
  ident: 10.1016/j.psychres.2010.07.049_bb0130
  article-title: Serotonin receptors: their key role in drugs to treat schizophrenia
  publication-title: Progress in Neuropsychopharmacology & Biological Psychiatry
  doi: 10.1016/j.pnpbp.2003.09.010
– volume: 62
  start-page: 195
  year: 2003
  ident: 10.1016/j.psychres.2010.07.049_bb0015
  article-title: Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia
  publication-title: Schizophrenia Research
  doi: 10.1016/S0920-9964(02)00284-0
SSID ssj0002199
Score 2.102059
Snippet Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty acids, has...
Abstract Abnormal fatty acid composition in neural membranes, that is, the balance between essential polyunsaturated fatty acids (EPUFAs) and saturated fatty...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 23
SubjectTerms Adult
Adult and adolescent clinical studies
Antipsychotic Agents - pharmacology
Antipsychotic Agents - therapeutic use
Antipsychotic drugs
Biological and medical sciences
Cell Membrane - drug effects
Cell Membrane - metabolism
Chronic Disease
Cognition
Erythrocytes - drug effects
Erythrocytes - metabolism
Erythrocytes - pathology
Essential polyunsaturated fatty acids
Fatty Acids - metabolism
Female
Humans
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Phospholipids
Predictive Value of Tests
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - metabolism
Schizophrenia - pathology
Social function
Statistics as Topic
Title Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0165178110004816
https://www.clinicalkey.es/playcontent/1-s2.0-S0165178110004816
https://dx.doi.org/10.1016/j.psychres.2010.07.049
https://www.ncbi.nlm.nih.gov/pubmed/20800904
https://www.proquest.com/docview/854379972
Volume 186
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Complete Freedom Collection [SCCMFC]
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 20191231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: ACRLP
  dateStart: 19950131
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1872-7123
  dateEnd: 20191231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: AIKHN
  dateStart: 19950131
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1872-7123
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002199
  issn: 0165-1781
  databaseCode: AKRWK
  dateStart: 19790701
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED9KC2MwRruvut2CHvaqxNZHLD2WspJtpC9bIW9ClmVI6ZwQuw972d--UySnLdvYWMEvNjosn-50d9bv7gDe28pyXjFJq1oJKpT01BbSUTR1mis1taUL-c7zy-nsSnxayMUenA-5MAFWmfb-uKdvd-v0ZJK4OVkvl5MvIRGnCImSsehJKLsdqn-hTI9_3ME8WOwhGQbTMPpelvD1eIsoxrA2QbzKcR5qav7eQD1b2w7Z1sR-F392SLeG6eIQniePkpzFSR_Bnm9fwJN5OjN_CYu5_4YhcetJY_v-O7FuWZObgBXqiMWLrDdhLMbeZNWQHfCcbCJ61pNlS1wsoUu6-xC9V3B18eHr-YymfgrUyZL3VFpX6sbpwnOrtFKWW-nraa0tczXqNS4SZ01hvWLeFo1TUkombK20RVuHVK9hv121_hiIL5oaydHsVUqI2mvNfM7xLgREjeAZyIGJxqVi46HnxY0ZUGXXZmC-Ccw3eWmQ-RlMdnTrWG7jrxTlsEZmSCbF7c-gRfg_St8lLe5MYTpmcvOLpGWgd5QPhPWf3jp6IEi7z2ToqXKhRAZkkCyDqh7Ob1BEVredUTIUj9Qly-BNlLg74uD461ycPGJmp_A0_jDnlOdvYb_f3Pp36HH11WirUiM4OPv4eXb5E0njLE8
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7SDbSFEvqu2zTVoVdnbT3W0jGEhk2T3UsT2JuQZRk2pN5l7Rz67ztayW5CW1JS8MVGg-XRaB7WNzMAn01pGCupSMtK8pRL4VKTC5uiqVNMyokprM93ns0n00v-dSEWO3Dc58J4WGXU_UGnb7V1fDKO3Byvl8vxN5-Ik_tEyVD0ZPIIdrlAnTyC3aPTs-l8UMg0tJH041NPcCtR-OpwCyrGyDaivIrDzJfV_LONerY2LXKuDi0v_u6Tbm3TyXPYi04lOQrzfgE7rnkJj2fx2PwVLGbuO0bFjSO16bofxNhlRa49XKglBi-y3vixGH6TVU0G7DnZBACtI8uG2FBFl7S3UXqv4fLky8XxNI0tFVIrCtalwthC1VbljhmppDTMCFdNKmWorXBr4zoxWufGSepMXlsphKDcVFIZNHdI9QZGzapx74C4vK6QHC1fKTmvnFLUZQzvfExUc5aA6Jmobaw37tteXOseWHale-Zrz3ydFRqZn8B4oFuHihv3UhT9Guk-nxQ1oEaj8DBK18aN3Opct1Rn-jdhS0ANlHfk9Z_eenBHkIbPpOisMi55AqSXLI273R_hoIisblotha8fqQqawNsgcb-Ive-vMv7-P2b2CZ5ML2bn-vx0fvYBnob_5yxl2T6Mus2N-4gOWFcexA32E2KZLvo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Membrane+fatty+acid+levels+as+a+predictor+of+treatment+response+in+chronic+schizophrenia&rft.jtitle=Psychiatry+research&rft.au=Sumiyoshi%2C+Tomiki&rft.au=Higuchi%2C+Yuko&rft.au=Matsui%2C+Mie&rft.au=Itoh%2C+Hiroko&rft.date=2011-03-30&rft.pub=Elsevier+Ireland+Ltd&rft.issn=0165-1781&rft.volume=186&rft.issue=1&rft.spage=23&rft.epage=27&rft_id=info:doi/10.1016%2Fj.psychres.2010.07.049&rft.externalDocID=S0165178110004816
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01651781%2FS0165178111X00033%2Fcov150h.gif